Broad-spectrum RNA antiviral inspired by ISG15-/- deficiency
Yemsratch T Akalu,Roosheel S Patel,Justin Taft,Rodrigo Canas-Arranz,Ashley Richardson,Sofija Buta,Marta Martin-Fernandez,Christos Sazeides,Rebecca L Pearl,Gayatri Mainkar,Andrew P Kurland,Rachel Geltman,Haylen Rosberger,Diana D Kang,Ann Anu Kurian,Keerat Kaur,Jennie Altman,Yizhou Dong,Jeffrey R Johnson,Lior Zhangi,Jean K Lim,Randy A Albrecht,Adolfo García-Sastre,Brad R Rosenberg,Dusan Bogunovic
DOI: https://doi.org/10.1101/2024.06.24.600468
2024-06-28
Abstract:Type I interferons (IFN-I) are cytokines with potent antiviral and inflammatory capacities. IFN-I signaling drives the expression of hundreds of IFN-I stimulated genes (ISGs), whose aggregate function results in the control of viral infection. A few of these ISGs are tasked with negatively regulating the IFN-I response to prevent overt inflammation. ISG15 is a negative regulator whose absence leads to persistent, low-grade elevation of ISG expression and concurrent, self-resolving mild autoinflammation. The limited breadth and low-grade persistence of ISGs expressed in ISG15 deficiency are sufficient to confer broad-spectrum antiviral resistance. Inspired by ISG15 deficiency, we have identified a nominal collection of 10 ISGs that recapitulate the broad antiviral potential of the IFN-I system. The expression of the 10 ISG collection in an IFN-I non-responsive cell line increased cellular resistance to Zika, Vesicular Stomatitis, Influenza A (IAV), and SARS-CoV-2 viruses. A deliverable prophylactic formulation of this syndicate of 10 ISGs significantly inhibited IAV PR8 replication in vivo in mice and protected hamsters against a lethal SARS-CoV-2 challenge, suggesting its potential as a broad-spectrum antiviral against many current and future emerging viral pathogens.
Immunology